Andrea Schilling1, Mercedes Macias Parra2, Maricruz Gutierrez3, Jaime Restrepo4, Santiago Ucros5, Teobaldo Herrera6, Eli Engel7, Luis Huicho8, Marcia Shew9, Roger Maansson10, Nicole Caldwell10, Alain Luxembourg10, Ajoke Sobanjo Ter Meulen10. 1. Facultad de Medicina Clinica Alemana-Universidad del Desarrollo, Santiago, Chile; dra.andrea.schilling@gmail.com. 2. Instituto Nacional de Pediatría, Mexico City, Mexico; 3. Hospital del Niño Poblano, Puebla, Mexico; 4. Fundacion Centro de Investigacion Clinica CIC, Medellín, Colombia; 5. Centro de Investigaciones en Salud, Fundacion Santa Fe de Bogotá, Bogotá, Colombia; 6. Insituto de Investigación Nutricional anexo Huáscar, Lima, Perú; 7. Bayview Research Group, Valley Village, California; 8. Instituto Nacional de Salud del Niño, Lima, Perú; 9. Indiana University School of Medicine/Department of Pediatrics, Indianapolis, Indiana; and. 10. Merck & Co., Inc., Kenilworth, New Jersey.
Abstract
BACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity and safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines routinely administered in this age group (Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] or Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). METHODS: Participants received 9vHPV vaccine at day 1 and months 2 and 6; the concomitant group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine at day 1; the nonconcomitant group (n = 620) received MCV4/Tdap at month 1. Antibodies to HPV-, MCV4-, and Tdap-relevant antigens were determined. Injection-site and systemic adverse events (AEs) were monitored for 15 days after any vaccination; serious AEs were monitored throughout the study. RESULTS: The geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3, proportion of subjects with a fourfold rise or greater in titers for 4 N meningitidis serotypes 4 weeks after injection with MCV4, proportion of subjects with antibody titers to diphtheria and tetanus ≥0.1 IU/mL, and geometric mean titers for pertussis antigens 4 weeks after injection with Tdap were all noninferior in the concomitant group compared with the nonconcomitant group. Injection-site swelling occurred more frequently in the concomitant group. There were no vaccine-related serious AEs. CONCLUSIONS: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere with the antibody response to any of these vaccines. This strategy would minimize the number of visits required to deliver each vaccine individually.
RCT Entities:
BACKGROUND: This study in 11- to 15-year-old boys and girls compared the immunogenicity and safety of GARDASIL 9 (9-valent human papillomavirus [9vHPV] vaccine) administered either concomitantly or nonconcomitantly with 2 vaccines routinely administered in this age group (Menactra [MCV4; Neisseria meningitidis serotypes A/C/Y/W-135] or Adacel [Tdap; diphtheria/tetanus/acellular pertussis]). METHODS:Participants received 9vHPV vaccine at day 1 and months 2 and 6; the concomitant group (n = 621) received MCV4/Tdap concomitantly with 9vHPV vaccine at day 1; the nonconcomitant group (n = 620) received MCV4/Tdap at month 1. Antibodies to HPV-, MCV4-, and Tdap-relevant antigens were determined. Injection-site and systemic adverse events (AEs) were monitored for 15 days after any vaccination; serious AEs were monitored throughout the study. RESULTS: The geometric mean titers for all HPV types in 9vHPV vaccine 4 weeks after dose 3, proportion of subjects with a fourfold rise or greater in titers for 4 N meningitidis serotypes 4 weeks after injection with MCV4, proportion of subjects with antibody titers to diphtheria and tetanus ≥0.1 IU/mL, and geometric mean titers for pertussis antigens 4 weeks after injection with Tdap were all noninferior in the concomitant group compared with the nonconcomitant group. Injection-site swelling occurred more frequently in the concomitant group. There were no vaccine-related serious AEs. CONCLUSIONS: Concomitant administration of 9vHPV vaccine with MCV4/Tdap was generally well tolerated and did not interfere with the antibody response to any of these vaccines. This strategy would minimize the number of visits required to deliver each vaccine individually.
Authors: Debbie Saslow; Kimberly S Andrews; Deana Manassaram-Baptiste; Lacey Loomer; Kristina E Lam; Marcie Fisher-Borne; Robert A Smith; Elizabeth T H Fontham Journal: CA Cancer J Clin Date: 2016-07-19 Impact factor: 508.702
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Ana Paula Ferreira Costa; Ricardo Ney Oliveira Cobucci; Janine Medeiros da Silva; Paulo Henrique da Costa Lima; Paulo César Giraldo; Ana Katherine Gonçalves Journal: J Immunol Res Date: 2017-07-24 Impact factor: 4.818
Authors: Lone K Petersen; Jaime Restrepo; Edson D Moreira; Ole-Erik Iversen; Punnee Pitisuttithum; Pierre Van Damme; Elmar A Joura; Sven-Erik Olsson; Daron Ferris; Stan Block; Anna R Giuliano; Xavier Bosch; Sophie Pils; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Donna Hyatt; Roger Maansson; Erin Moeller; Hong Qi; Christine Roberts; Alain Luxembourg Journal: Papillomavirus Res Date: 2017-03-16
Authors: C Signorelli; A Odone; V Ciorba; P Cella; R A Audisio; A Lombardi; L Mariani; F S Mennini; S Pecorelli; G Rezza; G V Zuccotti; A Peracino Journal: Epidemiol Infect Date: 2017-04-27 Impact factor: 4.434